T. T. Ashburn and K. B. Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov, vol.3, pp.673-83, 2004.

J. Langedijk, A. K. Mantel-teeuwisse, D. S. Slijkerman, and M. H. Schutjens, Drug repositioning and repurposing: terminology and definitions in literature, Drug Discov. Today, 2015.

J. S. Shim and J. O. Liu, Recent advances in drug repositioning for the discovery of new anticancer drugs, Int. J. Biol. Sci, issue.7, pp.654-63, 2014.

J. Lecomte, S. Flament, S. Salamone, M. Boisbrun, S. Mazerbourg et al., Grillier-Vuissoz, I. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines, Breast Cancer Res. Treat, vol.112, pp.437-51, 2008.

T. Fujita, Y. Sugiyama, S. Taketom, T. Shoda, Y. Kawamatsu et al., Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3870, U63287, ciglitazone), a new antidiabetic agent, Diabetes, vol.32, issue.9, pp.804-810, 1983.

C. Day, Thiazolidinediones: a new class of antidiabetic drugs, Diabet Med, vol.16, issue.3, pp.179-192, 1999.

M. Chojkier, Troglitazone and liver injury: in search of answers, Hepatology, vol.41, pp.237-283, 2005.

E. A. Gale, Troglitazone: the lesson that nobody learned? Diabetologia, vol.49, pp.1-6, 2006.

L. Chen, C. R. Bush, B. M. Necela, W. Su, M. Yanagisawa et al., RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells, Mol. Cell. Endocrinol, pp.17-32, 2006.

M. T. Smith, Mechanisms of Troglitazone Hepatotoxicity, Chem. Res. Toxicol, vol.16, pp.679-687, 2003.

T. Yokoi and . Troglitazone, Handb. Exp. Pharmacol, vol.196, pp.419-454, 2010.

C. W. Shiau, C. C. Yang, S. K. Kulp, K. F. Chen, C. S. Chen et al., Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma, Cancer Res, vol.65, pp.1561-1570, 2005.

M. A. Tirmenstein, C. X. Hu, T. L. Gales, B. E. Maleeff, P. K. Narayanan et al., Effects of troglitazone on HepG2 viability and mitochondrial function, Toxicol. Sci, vol.69, pp.131-139, 2002.

P. K. Narayanan, T. Hart, F. Elcock, C. Zhang, L. Hahn et al., Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment, Cytometry Part A, vol.52, issue.1, pp.28-35, 2003.

M. P. Bova, D. Tam, G. Mcmahon, and M. N. Mattson, Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells, Toxicol. Lett, vol.155, issue.1, pp.41-50, 2005.

P. L. Lim, J. Liu, M. L. Go, and U. A. Boelsterli, The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes, Toxicol. Sci, vol.101, pp.341-350, 2008.

L. I. Rachek, L. V. Yuzefovych, S. P. Ledoux, N. L. Julie, G. L. Wilson et al., but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes, Toxicol. Appl. Pharmacol, vol.240, issue.3, pp.348-54, 2009.

T. Okuda, M. Norioka, Y. Shitara, and T. Horie, Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition, Toxicol. Appl. Pharmacol, vol.248, pp.242-248, 2010.

D. Hu, C. Wu, Z. Li, Y. Liu, X. Fan et al., Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria, Toxicol. Appl. Pharmacol, vol.284, pp.134-141, 2015.

Y. H. Lee, W. W. Goh, C. K. Ng, M. Raida, L. Wong et al., Integrative toxicoproteomics implicates impaired mitochondrial glutathione import as an off-target effect of troglitazone, J Proteome Res, vol.12, issue.6, pp.2933-2978, 2013.

J. Yu, L. Qiao, L. Zimmermann, M. P. Ebert, H. Zhang et al., Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo, Hepatology, vol.43, pp.134-177, 2006.

T. Kubota, K. Koshizuka, E. A. Williamson, H. Asou, J. W. Said et al., Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo, Cancer Res, vol.58, pp.3344-52, 1998.

E. Elstner, C. Muller, K. Koshizuka, E. A. Williamson, D. Park et al., Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.8806-8817, 1998.

B. H. Aktas, Y. Qiao, E. Ozdelen, R. Schubert, S. Sevinc et al., Smallmolecule targeting of translation initiation for cancer therapy, Oncotarget, 1606.

L. Qiao, Y. Dai, Q. Gu, K. W. Chan, B. Zou et al., Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferatoractivated receptor gamma ligand-induced growth inhibition in colon cancer, Mol. Cancer Ther, vol.7, pp.2203-2214, 2008.

P. Sarraf, E. Mueller, D. Jones, F. J. King, D. J. Deangelo et al., Differentiation and reversal of malignant changes in colon cancer through PPARgamma, Nat. Med, vol.4, pp.1046-52, 1998.

K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells, J. Clin. Endocrinol. Metab, vol.86, pp.2170-2177, 2001.

W. Honma, M. Shimada, H. Sasano, S. Ozawa, M. Miyata et al., Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver, Drug Metab. Disposition, vol.30, pp.944-949, 2002.

C. Loi, M. Young, E. Randinitis, A. Vassos, and J. R. Koup, Clinical Pharmacokinetics of Troglitazone. Clin. Pharmacokinet, vol.37, pp.91-104, 1999.

Y. Yoshigae, K. Konno, W. Takasaki, and T. Ikeda, Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans, J. Toxicol. Sci, vol.25, issue.5, pp.433-474, 2000.

C. Funk, M. Pantze, L. Jehle, C. Ponelle, G. Scheuermann et al., Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate, Toxicology, vol.167, pp.83-98, 2001.

C. Funk, C. Ponelle, G. Scheuermann, and M. Pantze, Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat, Mol. Pharmacol, vol.59, issue.3, pp.627-662, 2001.

S. Saha and L. S. New,

H. K. Ho, W. K. Chui, and E. C. Chan, Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity, Toxicol. Lett, vol.192, pp.141-149, 2010.

R. Okada, K. Maeda, T. Nishiyama, S. Aoyama, Z. Tozuka et al., Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone, Drug Metab. Dispos, issue.12, pp.2290-2297, 2011.

E. Mueller, M. Smith, P. Sarraf, T. Kroll, A. Aiyer et al., Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer, Proc. Natl. Acad. Sci. U. S. A, vol.97, pp.10990-10995, 2000.

H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman et al., Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study, Breast Cancer Res. Treat, vol.79, pp.391-398, 2003.

M. H. Kulke, G. D. Demetri, N. E. Sharpless, D. P. Ryan, R. Shivdasani et al., A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer, Cancer J, vol.8, issue.5, pp.395-404, 2002.

F. Rashid-kolvear, M. A. Taboski, J. Nguyen, D. Y. Wang, L. A. Harrington et al., Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells, BMC Cancer, p.390, 2010.

T. O. Akinyeke and L. V. Stewart, Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgammaindependent mechanism, Cancer Biol. Ther, issue.12, pp.1046-58, 2011.

J. W. Huang, C. W. Shiau, Y. T. Yang, S. K. Kulp, K. F. Chen et al., Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells, Mol. Pharmacol, vol.67, pp.1342-1350, 2005.

S. Wei, L. F. Lin, C. C. Yang, Y. C. Wang, G. D. Chang et al., Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma, Mol. Pharmacol, vol.72, pp.725-758, 2007.

Z. Yang, R. Bagheri-yarmand, S. Balasenthil, G. Hortobagyi, A. A. Sahin et al., HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy, Clin. Cancer Res, vol.9, issue.8, pp.3198-203, 2003.

N. Hamaguchi, H. Hamada, S. Miyoshi, K. Irifune, R. Ito et al., In vitro and in vivo therapeutic efficacy of the PPAR-gamma agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth, Cancer Sci, vol.101, issue.9, pp.1955-64, 2010.

R. C. Reddy, A. Srirangam, K. Reddy, J. Chen, S. Gangireddy et al., Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer, Neoplasia, vol.10, issue.6, pp.597-603, 2008.

H. N. Yu, E. M. Noh, Y. R. Lee, S. G. Roh, E. K. Song et al., Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells, Biochem. Biophys. Res. Commun, vol.377, issue.1, pp.242-249, 2008.

Z. An, X. Liu, H. Song, C. Choi, W. D. Kim et al., Effect of troglitazone on radiation sensitivity in cervix cancer cells, Radiat Oncol J, vol.30, issue.2, pp.78-87, 2012.

C. Colin, S. Salamone, I. Grillier-vuissoz, M. Boisbrun, S. Kuntz et al., New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormoneindependent breast cancer cell lines, Breast Cancer Res. Treat, vol.124, pp.101-111, 2010.

C. Qin, R. Burghardt, R. Smith, M. Wormke, J. Stewart et al., Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells, Cancer Res, vol.63, issue.5, pp.958-64, 2003.

S. Salamone, C. Colin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al.,

M. Boisbrun, Synthesis of new troglitazone derivatives: Antiproliferative activity in breast cancer cell lines and preliminary toxicological study, Eur. J. Med. Chem, vol.51, pp.206-215, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00746870

J. Huang, C. Shiau, J. Yang, D. Wang, H. Chiu et al., Development of Small-Molecule Cyclin D1-Ablative Agents, J. Med. Chem, vol.49, pp.4684-4689, 2006.

, Current Topics in Medicinal Chemistry, vol.16, issue.22, 2016.

. Mazerbourg,

A. Bordessa, C. Colin-cassin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al., Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds, Eur. J. Med. Chem, vol.83, pp.129-140, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01094539

M. Boisbrun, Y. Chapleur, A. Bordessa, S. Flament, I. Grilliervuissoz et al., Thiazolidinediones derivatives, preparation thereof and use thereof in cancer treatment, Patent WO2013110796 (A1), 2013.

S. Saha, D. S. Chan, C. Y. Lee, W. Wong, L. S. New et al., Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their antidiabetic and anti-cancer properties, Eur. J. Pharmacol, vol.697, pp.13-23, 2012.

J. Yang, S. Wei, D. S. Wang, Y. C. Wang, S. K. Kulp et al., Pharmacological exploitation of the peroxisome proliferatoractivated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents, J. Med. Chem, issue.7, pp.2100-2107, 2008.

C. S. Chen, D. Wang, and J. Wang, Androgen receptot-ablative agents, Patent WO, 2009.

D. Wang, P. Chu, C. Yang, R. Yan, Y. Chuang et al., Development of a Novel Class of Glucose Transporter Inhibitors, J. Med. Chem, vol.55, pp.3827-3836, 2012.

J. H. Guh, W. L. Chang, J. Yang, S. L. Lee, S. Wei et al., Development of novel adenosine monophosphate-activated protein kinase activators, J. Med. Chem, issue.6, pp.2552-61, 2010.

K. H. Lee, E. C. Hsu, J. H. Guh, H. C. Yang, D. Wang et al., Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator, J. Biol. Chem, issue.45, pp.39247-58, 2011.

M. Meyer, S. Kuntz, I. Grillier-vuissoz, H. Martin, L. Richert et al., Synthesis and AntiProliferative Activity of New Biphenyle-Benzylidenethiazolidine-2,4-Dione Bis-Adducts Containing Various Heterocyclic Cores, Lett. Drug Des. Discov, vol.11, issue.3, pp.256-264, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01094215

C. Colin-cassin, X. Yao, C. Cerella, S. Chbicheb, S. Kuntz et al., Grillier-Vuissoz, I. PPAR?-inactive ?2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells: PPAR?-independent effects in breast cancer cells, Mol. Carcinog, vol.54, pp.393-404, 2015.

E. Chevet, C. Hetz, and A. Samali, Endoplasmic Reticulum StressActivated Cell Reprogramming in Oncogenesis, Cancer Discov, vol.5, issue.6, pp.586-597, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01152845

S. Chbicheb, X. Yao, J. Rodeau, S. Salamone, M. Boisbrun et al., EGR1 expression: A calcium and ERK1/2 mediated PPAR?-independent event involved in the antiproliferative effect of 15-deoxy-?12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells, Biochem. Pharmacol, vol.81, pp.1087-1097, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00685074

S. Kuntz, S. Mazerbourg, M. Boisbrun, C. Cerella, M. Diederich et al., Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones, Biochem. Pharmacol, vol.92, issue.1, pp.102-113, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01094216

S. H. Moon, S. J. Lee, K. H. Jung, C. H. Quach, J. W. Park et al., Troglitazone Stimulates Cancer Cell 18F-FDG uptake by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction, J. Nucl. Med, 2015.

M. L. Plissonnier, S. Fauconnet, H. Bittard, and I. Lascombe, Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells, Int. J. Cancer, issue.8, pp.1769-84, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00485114

W. Zou, X. Liu, P. Yue, F. R. Khuri, and S. Y. Sun, PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells, Cancer Biol. Ther, vol.6, pp.99-106, 2007.

M. Lu, T. Kwan, C. Yu, F. Chen, B. Freedman et al., Peroxisome proliferator-activated receptor gamma agonists promote TRAILinduced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest, J. Biol. Chem, issue.8, pp.6742-51, 2005.

I. .. Culture-cellulaire,

.. .. Iv, J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit et al., , vol.1, 2012.

W. D. Foulkes, I. E. Smith, and J. S. Reis-filho, Triple-negative breast cancer, N Engl J Med, vol.363, pp.1938-1948, 2010.

D. Zardavas, K. Tryfonidis, T. Goulioti, and M. Piccart, Targeted adjuvant therapy in breast cancer, Expert Rev Anticancer Ther, 2016.

L. A. Carey, C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan et al., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, vol.295, pp.2492-2502, 2006.

S. Lu, K. Singh, S. Mangray, R. Tavares, L. Noble et al., Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype, Mod Pathol, vol.26, pp.485-495, 2013.

A. M. Tokes, J. Kulka, S. Paku, A. Szik, C. Paska et al., Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study, Breast Cancer Res, vol.7, 2005.

S. Morohashi, T. Kusumi, F. Sato, H. Odagiri, H. Chiba et al., Decreased expression of claudin-1 correlates with recurrence status in breast cancer, Int J Mol Med, vol.20, pp.139-143, 2007.

A. M. Szasz, A. M. Tokes, M. Micsinai, T. Krenacs, C. Jakab et al., Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis, Clin Exp Metastasis, vol.28, pp.55-63, 2011.

F. Ma, X. Ding, Y. Fan, J. Ying, S. Zheng et al., A CLDN1-negative phenotype predicts poor prognosis in triplenegative breast cancer, PLoS ONE, vol.9, p.112765, 2014.

M. Furuse, H. Sasaki, K. Fujimoto, and S. Tsukita, A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts, J Cell Biol, vol.143, pp.391-401, 1998.

M. Saitou, K. Fujimoto, Y. Doi, M. Itoh, T. Fujimoto et al., Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions, J Cell Biol, vol.141, pp.397-408, 1998.

B. Zhou, A. Moodie, A. A. Blanchard, E. Leygue, and Y. Myal, Claudin 1 in breast cancer: new insights, J Clin Med, vol.4, pp.1960-1976, 2015.

, Breast Cancer Res Treat

K. Zhang, H. P. Yao, and M. H. Wang, Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility, Carcinogenesis, vol.29, pp.552-559, 2008.

M. Kulawiec, A. Safina, M. M. Desouki, I. Still, S. Matsui et al., Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion, Cancer Biol Ther, vol.7, pp.1732-1743, 2008.

T. Hoevel, R. Macek, K. Swisshelm, and M. Kubbies, Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids, Int J Cancer, vol.108, pp.374-383, 2004.

H. Akasaka, F. Sato, S. Morohashi, Y. Wu, Y. Liu et al., Anti-apoptotic effect of claudin-1 in tamoxifen-treated human breast cancer MCF-7 cells, BMC Cancer, vol.10, p.548, 2010.

Y. Liu, L. Wang, X. L. Lin, J. Wang, J. H. Yu et al., Anti-apoptotic effect of claudin-1 on TNF-a-induced apoptosis in human breast cancer MCF-7, Tumor Biol, vol.33, pp.2307-2315, 2012.

B. Zhou, A. Blanchard, N. Wang, X. Ma, J. Han et al., Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7, Cancer Invest, vol.33, pp.429-439, 2015.

E. Frohlich and R. Wahl, Chemotherapy and chemoprevention by thiazolidinediones, Biomed Res Int, p.845340, 2015.

P. D. Home, S. J. Pocock, H. Beck-nielsen, P. S. Curtis, R. Gomis et al., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, vol.373, pp.2125-2135, 2009.

M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials, Diabetes Care, vol.31, pp.1455-1460, 2008.

E. Mueller, M. Smith, P. Sarraf, T. Kroll, A. Aiyer et al., Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer, 2000.

, Proc Natl Acad Sci, vol.97, pp.10990-10995

S. Prost, F. Relouzat, M. Spentchian, Y. Ouzegdouh, J. Saliba et al., Erosion of the chronic myeloid leukaemia stem cell pool by PPAR gamma agonists, Nature, 2015.

M. Chojkier, Troglitazone and liver injury: in search of answers, Hepatology, vol.41, pp.237-246, 2005.

S. Salamone, C. Colin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al., Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study, Eur J Med Chem, vol.51, pp.206-215, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00746870

J. Lecomte, S. Flament, S. Salamone, M. Boisbrun, S. Mazerbourg et al., Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines, Breast Cancer Res Treat, vol.112, pp.437-451, 2008.

C. Colin, S. Salamone, I. Grillier-vuissoz, M. Boisbrun, S. Kuntz et al., New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines, Breast Cancer Res Treat, vol.124, pp.101-110, 2010.

C. Colin-cassin, X. Yao, C. Cerella, S. Chbicheb, S. Kuntz et al., PPARgamma-inactive Delta2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells, Mol Carcinog, vol.54, pp.393-404, 2015.

D. Cello, F. Cope, L. Li, H. Jeschke, J. Wang et al., Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer, PLoS ONE, vol.8, p.68630, 2013.

N. Ogasawara, T. Kojima, M. Go, T. Ohkuni, J. Koizumi et al., PPARgamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells, Pharmacol Res, vol.61, issue.6, pp.489-498, 2010.

C. L. Varley, M. A. Garthwaite, W. Cross, J. Hinley, and L. K. Trejdosiewicz, PPARgamma-regulated tight junction development during human urothelial cytodifferentiation, J Cell Physiol, vol.208, pp.407-417, 2006.

S. Kumei, W. Motomura, T. Yoshizaki, K. Takakusaki, and T. Okumura, Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells, Biochem Biophys Res Commun, vol.380, pp.614-619, 2009.

T. Okumura, Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs, J Gastroenterol, vol.45, pp.1097-1102, 2010.

N. Beeman, P. G. Webb, and H. K. Baumgartner, Occludin is required for apoptosis when claudin-claudin interactions are disrupted, Cell Death Dis, vol.3, p.273, 2012.

A. M. Fortier, E. Asselin, and M. Cadrin, Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation, J Biol Chem, vol.288, pp.11555-11571, 2013.

C. Zihni, C. Mills, K. Matter, and M. S. Balda, Tight junctions: from simple barriers to multifunctional molecular gates, Breast Cancer Res Treat References, vol.17, pp.564-580, 2016.

C. M. Van-itallie, A. J. Tietgens, A. , and J. M. , Visualizing the dynamic coupling of claudin strands to the actin cytoskeleton through ZO-1, Mol. Biol. Cell, vol.28, pp.524-534, 2017.

M. L. Gardel, I. C. Schneider, Y. Aratyn-schaus, and C. M. Waterman, Mechanical integration of actin and adhesion dynamics in cell migration, Annu. Rev. Cell Dev. Biol, vol.26, pp.315-333, 2010.

S. Morohashi, T. Kusumi, F. Sato, H. Odagiri, H. Chiba et al., Decreased expression of claudin-1 correlates with recurrence status in breast cancer, Int. J. Mol. Med, vol.20, pp.139-143, 2007.

A. M. Szasz, A. M. Tokes, M. Micsinai, T. Krenacs, C. Jakab et al., Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis, Clin. Exp. Metastasis, vol.28, pp.55-63, 2011.

F. Ma, X. Ding, Y. Fan, J. Ying, S. Zheng et al., A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer, PLoS ONE, vol.9, 2014.

B. Zhou, A. Moodie, A. A. Blanchard, E. Leygue, and Y. Myal, Claudin 1 in Breast Cancer: New Insights, J Clin Med, vol.4, pp.1960-1976, 2015.

M. Geoffroy, A. Kleinclauss, S. Grandemange, S. Hupont, M. Boisbrun et al., Pro-apoptotic effect of ?2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1, Breast Cancer Res. Treat, vol.165, pp.517-527, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01589665

E. Fröhlich, R. Wahl, S. Prost, F. Relouzat, M. Spentchian et al., Erosion of the chronic myeloid leukaemia stem cell pool by PPAR? agonists, Biomed Res Int, vol.845340, pp.380-383, 2015.

M. Chojkier, Troglitazone and liver injury: in search of answers, Hepatology, vol.41, pp.237-246, 2005.

S. Salamone, C. Colin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al., Synthesis of new troglitazone derivatives: antiproliferative activity in breast cancer cell lines and preliminary toxicological study, Eur J Med Chem, vol.51, pp.206-215, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00746870

A. Bordessa, C. Colin-cassin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al., Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds, Eur J Med Chem, vol.83, pp.129-140, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01094539

C. Colin-cassin, X. Yao, C. Cerella, S. Chbicheb, S. Kuntz et al., PPAR?-inactive ?2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells, Mol. Carcinog, vol.54, pp.393-404, 2015.

J. Lehtimäki, M. Hakala, and P. Lappalainen, Actin Filament Structures in Migrating Cells, 2017.

, Handb Exp Pharmacol, vol.235, pp.123-152

W. Motomura, M. Nagamine, S. Tanno, M. Sawamukai, N. Takahashi et al., Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells, J. Gastroenterol, vol.39, pp.461-468, 2004.

Y. Yang, T. Ho, S. Chen, H. Lai, J. Wu et al., Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line, BMC Cancer, vol.7, p.216, 2007.

P. Wang, F. Chou, L. Porchia, M. Saji, and J. J. Pinzone, Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells, Mol. Carcinog, vol.47, pp.905-915, 2008.

C. Blanquicett, J. Roman, and C. M. Hart, Thiazolidinediones as anti-cancer agents, Cancer Ther, vol.6, pp.25-34, 2008.

J. Liu, H. Lu, R. Huang, D. Lin, X. Wu et al., , 2005.

, Peroxisome proliferator activated receptor-? ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells, Cancer Chemother Pharmacol, vol.56, pp.400-408

J. Aizawa, K. Sakayama, S. Kamei, T. Kidani, H. Yamamoto et al., Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. BMC Cancer 10, 51. 22. Dukes, Anticancer Res, vol.7, pp.851-857, 2009.

K. Swisshelm, A. Machl, S. Planitzer, R. Robertson, M. Kubbies et al., SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily, Gene, vol.226, pp.285-295, 1999.

X. Li, W. Liu, X. Chen, Y. Wang, D. Shi et al., Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancer, Int. J. Mol. Med, vol.39, pp.927-935, 2017.

M. Basu, I. Sengupta, M. W. Khan, D. K. Srivastava, P. Chakrabarti et al., , 2017.

, Dual histone reader ZMYND8 inhibits cancer cell invasion by positively regulating epithelial genes

, Biochem. J, vol.474, pp.1919-1934

J. Hou, Z. Wang, H. Xu, L. Yang, X. Yu et al., Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling, PLoS ONE, vol.10, p.122179, 2015.

A. Majer, A. A. Blanchard, S. Medina, S. A. Booth, and Y. Myal, Claudin 1 Expression Levels Affect miRNA Dynamics in Human Basal-Like Breast Cancer Cells, DNA Cell Biol, vol.35, pp.328-339, 2016.

B. Zhou, A. Blanchard, N. Wang, X. Ma, J. Han et al., , 2015.

, Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7, Cancer Invest, vol.33, pp.429-439

R. Bibliographiques-a-acea and . Biosciences,

M. Ahmadian, J. M. Suh, N. Hah, C. Liddle, A. R. Atkins et al., PPAR? signaling and metabolism: the good, the bad and the future, Nat. Med, vol.19, pp.557-566, 2013.

S. G. Ahn, S. J. Kim, C. Kim, J. , and J. , Molecular Classification of Triple-Negative Breast Cancer, J Breast Cancer, vol.19, pp.223-230, 2016.

J. Aizawa, K. Sakayama, S. Kamei, T. Kidani, H. Yamamoto et al., Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8, BMC Cancer, vol.10, p.51, 2010.

H. Akasaka, F. Sato, S. Morohashi, Y. Wu, Y. Liu et al.,

, Anti-apoptotic effect of claudin-1 in tamoxifen-treated human breast cancer MCF-7 cells, BMC Cancer, vol.10, p.548

Y. Akasaki, G. Liu, H. H. Matundan, H. Ng, X. Yuan et al., A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells, J. Biol. Chem, vol.281, pp.6165-6174, 2006.

T. O. Akinyeke and L. V. Stewart, Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPAR?-independent mechanism, Cancer Biol. Ther, vol.11, pp.1046-1058, 2011.

M. Al-hajj, M. S. Wicha, A. Benito-hernandez, S. J. Morrison, C. et al., Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. U.S.A, vol.100, pp.3983-3988, 2003.

M. Amasheh, A. Fromm, S. M. Krug, S. Amasheh, S. Andres et al.,

, TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling, J. Cell. Sci, vol.123, pp.4145-4155

J. M. Anderson and C. M. Van-itallie, Physiology and Function of the Tight Junction, Cold Spring Harb Perspect Biol, vol.1, 2009.

, Angadi Epithelial-mesenchymal transition -A fundamental mechanism in cancer progression: An overview

, Associate Degree Nursing Physiology Review

B. Auffinger, A. L. Tobias, Y. Han, G. Lee, D. Guo et al., Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy, Cell Death Differ, vol.21, pp.1119-1131, 2013.

O. J. Baker, J. M. Camden, R. S. Redman, J. E. Jones, C. I. Seye et al., , 2008.

, Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma alter tight junction structure and function in the rat parotid gland Par-C10 cell line, Am. J. Physiol, vol.295, pp.1191-1201

M. Basu, I. Sengupta, M. W. Khan, D. K. Srivastava, P. Chakrabarti et al., Dual histone reader ZMYND8 inhibits cancer cell invasion by positively regulating epithelial genes, Biochem. J, vol.474, pp.1919-1934, 2017.

H. K. Baumgartner, M. C. Rudolph, P. Ramanathan, V. Burns, P. Webb et al., Developmental Expression of Claudins in the Mammary Gland, J Mammary Gland Biol Neoplasia, vol.22, pp.141-157, 2017.

N. Beeman, P. G. Webb, and H. K. Baumgartner, Occludin is required for apoptosis when claudinclaudin interactions are disrupted, Cell Death Dis, vol.3, p.273, 2012.

H. Benachour, T. Bastogne, M. Toussaint, Y. Chemli, A. Sève et al., Real-Time Monitoring of Photocytotoxicity in NanoparticlesBased Photodynamic Therapy: A Model-Based Approach, PLOS ONE, vol.7, p.48617, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00742724

C. J. Bentzel, B. Hainau, S. Ho, S. W. Hui, A. Edelman et al., , 1980.

, Cytoplasmic regulation of tight-junction permeability: effect of plant cytokinins, Am. J. Physiol, vol.239, pp.75-89

J. Berger, P. Bailey, C. Biswas, C. A. Cullinan, T. W. Doebber et al., Thiazolidinediones produce a conformational change in peroxisomal proliferatoractivated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice, Endocrinology, vol.137, pp.4189-4195, 1996.

A. A. Bhat, A. Sharma, J. Pope, M. Krishnan, M. K. Washington et al., Caudal homeobox protein Cdx-2 cooperates with Wnt pathway to regulate claudin-1 expression in colon cancer cells, PLoS ONE, vol.7, p.37174, 2012.

A. A. Bhat, R. Ahmad, S. B. Uppada, A. B. Singh, and P. Dhawan, Claudin-1 promotes TNF-?-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells, Exp. Cell Res, vol.349, pp.119-127, 2016.

A. A. Blanchard, G. P. Skliris, P. H. Watson, L. C. Murphy, C. Penner et al., Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype, Virchows Arch, vol.454, pp.647-656, 2009.

A. A. Blanchard, X. Ma, K. J. Dueck, C. Penner, S. C. Cooper et al., Claudin 1 expression in basal-like breast cancer is related to patient age, BMC Cancer, vol.13, p.268, 2013.

C. Blanquicett, J. Roman, and C. M. Hart, Thiazolidinediones as anti-cancer agents, Cancer Ther, vol.6, pp.25-34, 2008.

M. Boisbrun, Y. Chapleur, A. Bordessa, S. Flament, I. Grillier-vuissoz et al., Dérivés de thiazolidinedione, leur preparation et leur utilisation dans le traitement des cancers, 2013.

A. Bordessa, C. Colin-cassin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al., Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds, Eur J Med Chem, vol.83, pp.129-140, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01094539

M. D. Brooks, M. L. Burness, and M. S. Wicha, Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer, Cell Stem Cell, vol.17, pp.260-271, 2015.

H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman et al., Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study, Breast Cancer Res. Treat, vol.79, pp.391-397, 2003.

A. M. Butt, I. B. Khan, M. Hussain, M. Idress, J. Lu et al., Role of post translational modifications and novel crosstalk between phosphorylation and O-beta-GlcNAc modifications in human claudin-1, Mol. Biol. Rep, vol.39, pp.1359-1369, 2012.

R. Cailleau, R. Young, M. Olivé, and W. J. Reeves, Breast tumor cell lines from pleural effusions, J Natl Cancer Inst, vol.53, pp.661-674, 1974.

H. K. Campbell, J. L. Maiers, and K. A. Demali, Interplay between tight junctions & adherens junctions, Exp. Cell Res, vol.358, pp.39-44, 2017.

C. T. Capaldo and A. Nusrat, Claudin switching: Physiological plasticity of the Tight Junction, Semin. Cell Dev. Biol, vol.42, pp.22-29, 2015.

M. Cereijido, I. Meza, and A. Martínez-palomo, Occluding junctions in cultured epithelial monolayers, Am. J. Physiol, vol.240, pp.96-102, 1981.

T. L. Chang, K. Ito, T. K. Ko, Q. Liu, M. Salto-tellez et al., , 2010.

, Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells, Gastroenterology, vol.138, pp.255-265

Y. Chao, S. Pan, S. Yang, S. Yu, T. Che et al., Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma, Am. J. Respir. Crit. Care Med, vol.179, pp.123-133, 2009.

S. Chbicheb, X. Yao, J. Rodeau, S. Salamone, M. Boisbrun et al., EGR1 expression: a calcium and ERK1/2 mediated PPAR?-independent event involved in the antiproliferative effect of 15-deoxy-?12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells, Biochem. Pharmacol, vol.81, pp.1087-1097, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00685074

S. Chen and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J. Clin. Oncol, vol.25, pp.1329-1333, 2007.

Y. Chen, M. You, Q. Chong, V. Pandey, Q. Zhuang et al., Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression, Int J Mol Sci, vol.18, 2017.

Q. Chi, T. Yin, H. Gregersen, X. Deng, Y. Fan et al., Rear actomyosin contractility-driven directional cell migration in three-dimensional matrices: a mechano-chemical coupling mechanism, J R Soc Interface, vol.11, 2014.

M. Chojkier, Troglitazone and liver injury: in search of answers, Hepatology, vol.41, pp.237-246, 2005.

C. Chou, N. Chang, S. Shrestha, S. Hsu, Y. Lin et al., miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database, Nucleic Acids Res, vol.44, pp.239-247, 2016.

A. Chung, X. Cui, W. Audeh, and A. Giuliano, Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance, Clin. Breast Cancer, vol.13, pp.223-232, 2013.

S. Citi, H. Sabanay, R. Jakes, B. Geiger, K. et al., Cingulin, a new peripheral component of tight junctions, Nature, vol.333, pp.272-276, 1988.

S. Citi, H. Sabanay, J. Kendrick-jones, and B. Geiger, Cingulin: characterization and localization, J. Cell. Sci, vol.93, pp.107-122, 1989.

O. R. Colegio, C. Van-itallie, C. Rahner, A. , and J. M. , Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture, Am. J. Physiol, vol.284, pp.1346-1354, 2003.

C. Colin, S. Salamone, I. Grillier-vuissoz, M. Boisbrun, S. Kuntz et al., New troglitazone derivatives devoid of PPAR? agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines, Breast Cancer Res. Treat, vol.124, pp.101-110, 2010.

C. Colin-cassin, X. Yao, C. Cerella, S. Chbicheb, S. Kuntz et al., PPAR?-inactive ?2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells, Mol. Carcinog, vol.54, pp.393-404, 2015.

J. Collignon, L. Lousberg, H. Schroeder, and G. Jerusalem, Triple-negative breast cancer: treatment challenges and solutions, Breast Cancer, vol.8, pp.93-107, 2016.

C. J. Creighton, X. Li, M. Landis, J. M. Dixon, V. M. Neumeister et al., Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc. Natl. Acad. Sci. U.S.A, vol.106, pp.13820-13825, 2009.

C. M. Cuda, R. M. Pope, and H. Perlman, The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases, Nat Rev Rheumatol, vol.12, pp.543-558, 2016.

P. Dahan, J. Martinez-gala, C. Delmas, S. Monferran, L. Malric et al., Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance, Cell Death Dis, vol.5, 1543.

S. Dawood, K. Broglio, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review, J. Clin. Oncol, vol.28, pp.92-98, 2010.

C. Day, Thiazolidinediones: a new class of antidiabetic drugs, Diabet. Med, vol.16, pp.179-192, 1999.

G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-rychter, R. Oyen et al., A phase II trial with rosiglitazone in liposarcoma patients, Br. J. Cancer, vol.89, pp.1409-1412, 2003.

G. D. Demetri, C. D. Fletcher, E. Mueller, P. Sarraf, R. Naujoks et al., Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma, Proc. Natl. Acad. Sci. U.S.A, vol.96, pp.3951-3956, 1999.

A. Denelavas, F. Weibel, M. Prummer, A. Imbach, R. G. Clerc et al., Real-time cellular impedance measurements detect Ca(2+) channel-dependent oscillations of morphology in human H295R adrenoma cells, Biochim. Biophys. Acta, vol.1813, pp.754-762, 2011.

R. Dent, W. M. Hanna, M. Trudeau, E. Rawlinson, P. Sun et al., Pattern of metastatic spread in triple-negative breast cancer, Breast Cancer Res. Treat, vol.115, pp.423-428, 2009.

P. Dhawan, A. B. Singh, N. G. Deane, Y. No, S. Shiou et al., Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer, J. Clin. Invest, vol.115, pp.1765-1776, 2005.

F. Di-cello, L. Cope, H. Li, J. Jeschke, W. Wang et al., Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer, PLoS ONE, vol.8, p.68630, 2013.

M. Di-modica, E. Tagliabue, and T. Triulzi, Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host, Dis. Markers, p.7849108, 2017.

L. Ding, Z. Lu, O. Foreman, R. Tatum, Q. Lu et al., Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice, Gastroenterology, vol.142, pp.305-315, 2012.

H. S. Duffy, G. R. John, S. C. Lee, C. F. Brosnan, and D. C. Spray, Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1beta in primary human fetal astrocytes, J. Neurosci, vol.20, p.114, 2000.

J. Dufresne and D. G. Cyr, Activation of an SP binding site is crucial for the expression of claudin 1 in rat epididymal principal cells, Biol. Reprod, vol.76, pp.825-832, 2007.

J. D. Dukes, P. Whitley, C. , and A. D. , The PIKfyve inhibitor YM201636 blocks the continuous recycling of the tight junction proteins claudin-1 and claudin-2 in MDCK cells, PLoS ONE, vol.7, p.28659, 2012.

J. E. Duncan, L. S. Goldstein, Y. Fan, H. Chen, A. Natarajan et al., Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium, Bioorg. Med. Chem. Lett, vol.14, pp.2547-2550, 2004.

A. S. Fanning, B. J. Jameson, L. A. Jesaitis, A. , and J. M. , The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton, J. Biol. Chem, vol.273, pp.29745-29753, 1998.

A. S. Fanning, C. M. Van-itallie, A. , and J. M. , Zonula occludens-1 and -2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia, Mol. Biol. Cell, vol.23, pp.577-590, 2012.

M. G. Farquhar and G. E. Palade, Junctional complexes in various epithelia, J. Cell Biol, vol.17, pp.375-412, 1963.

E. Filipova, K. Uzunova, K. Kalinov, and T. Vekov, Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis, Diabetes Ther, vol.8, pp.705-726, 2017.

D. A. Fletcher and R. D. Mullins, Cell mechanics and the cytoskeleton, Nature, vol.463, pp.485-492, 2010.

A. Fortier, E. Asselin, and M. Cadrin, Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation, J. Biol. Chem, vol.288, pp.11555-11571, 2013.

W. D. Foulkes, I. E. Smith, and J. S. Reis-filho, Triple-negative breast cancer, N. Engl. J. Med, vol.363, pp.1938-1948, 2010.

A. D. French, J. L. Fiori, T. C. Camilli, P. D. Leotlela, M. P. O'connell et al., PKC and PKA phosphorylation affect the subcellular localization of claudin-1 in melanoma cells, Int J Med Sci, vol.6, pp.93-101, 2009.

E. Fröhlich and R. Wahl, Chemotherapy and chemoprevention by thiazolidinediones, Biomed Res Int, p.845340, 2015.

M. Fujibe, H. Chiba, T. Kojima, T. Soma, T. Wada et al., Thr203 of claudin-1, a putative phosphorylation site for MAP kinase, is required to promote the barrier function of tight junctions, Exp. Cell Res, vol.295, pp.36-47, 2004.

M. Fujita, T. Yagami, M. Fujio, C. Tohji, K. Takase et al., Cytotoxicity of troglitazone through PPAR?-independent pathway and p38 MAPK pathway in renal cell carcinoma, Cancer Lett, vol.312, pp.219-227, 2011.

T. Fujita, Y. Sugiyama, S. Taketomi, T. Sohda, Y. Kawamatsu et al., Reduction of insulin resistance in obese and/or diabetic animals by 5, Diabetes, vol.287, pp.804-810, 1983.

M. Furuse, Molecular basis of the core structure of tight junctions, Cold Spring Harb Perspect Biol, vol.2, p.2907, 2010.

M. Furuse, K. Fujita, T. Hiiragi, K. Fujimoto, and S. Tsukita, Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin, J. Cell Biol, vol.141, pp.1539-1550, 1998.

M. Furuse, H. Sasaki, K. Fujimoto, and S. Tsukita, A Single Gene Product, Claudin-1 or -2, Reconstitutes Tight Junction Strands and Recruits Occludin in Fibroblasts, J Cell Biol, vol.143, pp.391-401, 1998.

Z. Gan, L. Ding, C. J. Burckhardt, J. Lowery, A. Zaritsky et al., Vimentin Intermediate Filaments Template Microtubule Networks to Enhance Persistence in Cell Polarity and Directed Migration, Cell Syst, vol.3, pp.252-263, 2016.

A. Galli, E. Ceni, D. W. Crabb, T. Mello, R. Salzano et al., Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms, Gut, vol.53, pp.1688-1697, 2004.

M. L. Gardel, I. C. Schneider, Y. Aratyn-schaus, and C. M. Waterman, Mechanical integration of actin and adhesion dynamics in cell migration, Annu. Rev. Cell Dev. Biol, vol.26, pp.315-333, 2010.

M. Geoffroy, A. Kleinclauss, S. Grandemange, S. Hupont, M. Boisbrun et al., Pro-apoptotic effect of ?2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1, Breast Cancer Res. Treat, vol.165, pp.517-527, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01589665

R. Gerhard, S. Ricardo, A. Albergaria, M. Gomes, A. R. Silva et al., Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas, Breast, vol.21, pp.354-360, 2012.

B. N. Giepmans and S. C. Van-ijzendoorn, Epithelial cell-cell junctions and plasma membrane domains, Biochim. Biophys. Acta, vol.1788, pp.820-831, 2009.

C. Ginestier, H. Korkaya, G. Dontu, D. Birnbaum, M. S. Wicha et al., , 2007.

, Med Sci (Paris), vol.23, pp.1133-1139, 2012.

L. G. Glotfelty, A. Zahs, C. Iancu, L. Shen, and G. A. Hecht, Microtubules are required for efficient epithelial tight junction homeostasis and restoration, Am. J. Physiol, vol.307, pp.245-254, 2014.

L. González-mariscal, S. Lechuga, and E. Garay, Role of tight junctions in cell proliferation and cancer, Prog Histochem Cytochem, vol.42, pp.1-57, 2007.

L. González-mariscal, R. Tapia, and D. Chamorro, Crosstalk of tight junction components with signaling pathways, Biochim. Biophys. Acta, vol.1778, pp.729-756, 2008.

M. Grände, A. Franzen, J. Karlsson, L. E. Ericson, N. Heldin et al., Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes, J. Cell. Sci, vol.115, pp.4227-4236, 2002.

M. Greaves and C. C. Maley, Clonal evolution in cancer, Nature, vol.481, pp.306-313, 2012.

C. R. Green and P. R. Bergquist, Phylogenetic Relationships within Theinvertebrata in Relation to Thestructure of Septate Junctions and the development of 'Occluding' Junctional Types, Journal of Cell Science, vol.53, pp.279-305, 1982.

I. Grillier-vuissoz, S. Mazerbourg, M. Boisbrun, R. Kuntz, Y. Chapleur et al., PPARÃ Â 3 -independent Activity of Thiazolidinediones: A Promising Mechanism of Action for New Anticancer Drugs, 2012.

C. Grommes, G. E. Landreth, M. Sastre, M. Beck, D. L. Feinstein et al., Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment, Mol. Pharmacol, vol.70, pp.1524-1533, 2006.

B. Grosse, D. Cassio, N. Yousef, C. Bernardo, E. Jacquemin et al., Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability, Hepatology, vol.55, pp.1249-1259, 2012.

D. Günzel and M. Fromm, Claudins and other tight junction proteins, Compr Physiol, vol.2, pp.1819-1852, 2012.

D. Günzel, Y. , and A. S. , Claudins and the modulation of tight junction permeability, Physiol. Rev, vol.93, pp.525-569, 2013.

P. S. Gurel, A. L. Hatch, and H. N. Higgs, Connectingthe puzzle pieces between cytoskeleton andsecretory pathway, Curr Biol, vol.24, pp.660-672, 2014.

A. J. Hackett, H. S. Smith, E. L. Springer, R. B. Owens, W. A. Nelson-rees et al., Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines, J. Natl. Cancer Inst, vol.58, pp.1795-1806, 1977.

S. Hadj-rabia, L. Baala, P. Vabres, D. Hamel-teillac, E. Jacquemin et al., Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease, Gastroenterology, vol.127, pp.1386-1390, 2004.

S. J. Hagen, Non-canonical functions of claudin proteins: Beyond the regulation of cell-cell adhesions, Tissue Barriers, vol.5, p.1327839, 2017.

S. Halford, P. Spencer, J. Greenwood, H. Winton, D. M. Hunt et al., Assignment of claudin-1 (CLDN1) to human chromosome 3q28-->q29 with somatic cell hybrids, Cytogenet. Cell Genet, vol.88, p.217, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

F. Hassiotou, A. Beltran, E. Chetwynd, A. M. Stuebe, A. Twigger et al., Breastmilk is a novel source of stem cells with multilineage differentiation potential, Stem Cells, vol.30, pp.2164-2174, 2012.

A. S. Hauser, M. M. Attwood, M. Rask-andersen, H. B. Schiöth, and D. E. Gloriam, Trends in GPCR drug discovery: new agents, targets and indications, Nat Rev Drug Discov, vol.16, pp.829-842, 2017.

B. T. Hennessy, A. Gonzalez-angulo, K. Stemke-hale, M. Z. Gilcrease, S. Krishnamurthy et al., Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics, Cancer Res, vol.69, pp.4116-4124, 2009.

H. Herrmann, S. V. Strelkov, P. Burkhard, A. , and U. , Intermediate filaments: primary determinants of cell architecture and plasticity, J. Clin. Invest, vol.119, pp.1772-1783, 2009.

J. I. Herschkowitz, K. Simin, V. J. Weigman, I. Mikaelian, J. Usary et al., Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biol, vol.8, p.76, 2007.

Y. Higashi, S. Suzuki, T. Sakaguchi, T. Nakamura, S. Baba et al., Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma, J. Surg. Res, vol.139, pp.68-76, 2007.

T. Hoevel, R. Macek, O. Mundigl, K. Swisshelm, and M. Kubbies, Expression and targeting of the tight junction protein CLDN1 in CLDN1-negative human breast tumor cells, J. Cell. Physiol, vol.191, pp.60-68, 2002.

T. Hoevel, R. Macek, K. Swisshelm, and M. Kubbies, Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids, Int. J. Cancer, vol.108, pp.374-383, 2004.

J. Hou, Z. Wang, H. Xu, L. Yang, X. Yu et al., , 2015.

, Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling, PLoS ONE, vol.10, p.122179

K. L. Howe, C. Reardon, A. Wang, A. Nazli, and D. M. Mckay, Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability, Am. J. Pathol, vol.167, pp.1587-1597, 2005.

A. Howell and A. M. Wardley, Overview of the impact of conventional systemic therapies on breast cancer, Endocr. Relat. Cancer, vol.12, issue.1, pp.9-16, 2005.

J. Huang, C. Shiau, Y. Yang, S. K. Kulp, K. Chen et al., Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells, Mol. Pharmacol, vol.67, pp.1342-1348, 2005.

Q. Huo, T. Kinugasa, L. Wang, J. Huang, J. Zhao et al., Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer, Anticancer Res, vol.29, pp.851-857, 2009.

A. Ichimura, A. Hirasawa, T. Hara, and G. Tsujimoto, Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis, Prostaglandins Other Lipid Mediat, vol.89, pp.82-88, 2009.

A. Ikari, K. Atomi, A. Takiguchi, Y. Yamazaki, M. Miwa et al., Epidermal growth factor increases claudin-4 expression mediated by Sp1 elevation in MDCK cells, Biochem. Biophys. Res. Commun, vol.384, pp.306-310, 2009.

J. Ikenouchi, M. Furuse, K. Furuse, H. Sasaki, S. Tsukita et al., Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells, J. Cell Biol, vol.171, pp.939-945, 2005.

T. Inai, J. Kobayashi, and Y. Shibata, Claudin-1 contributes to the epithelial barrier function in MDCK cells, Eur. J. Cell Biol, vol.78, pp.849-855, 1999.

C. Jackisch, H. A. Hahm, B. Tombal, D. Mccloskey, K. Butash et al., , 2000.

, Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells, Clin. Cancer Res, vol.6, pp.2844-2850

K. Jain and A. Basu, Protein Kinase C-? Promotes EMT in Breast Cancer, Breast Cancer (Auckl), vol.8, pp.61-67, 2014.

H. Jan, C. Lee, Y. Lin, J. Lai, H. Wei et al., Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells, Cancer Lett, vol.277, pp.141-148, 2009.

E. V. Jensen, J. , and V. C. , The estrogen receptor: a model for molecular medicine, Clin. Cancer Res, vol.9, 1980.

S. R. Johnston and M. Dowsett, Aromatase inhibitors for breast cancer: lessons from the laboratory, Nat. Rev. Cancer, vol.3, pp.821-831, 2003.

J. Lieff-website,

H. Joshi, T. Pal, and C. S. Ramaa, A new dawn for the use of thiazolidinediones in cancer therapy, Expert Opin Investig Drugs, vol.23, pp.501-510, 2014.

J. H. Jung, C. K. Jung, H. J. Choi, K. H. Jun, J. Yoo et al., Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas, Pathol. Res. Pract, vol.205, pp.409-416, 2009.

E. Kebebew, M. Peng, E. Reiff, P. Treseler, K. A. Woeber et al., A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer, Surgery, vol.140, pp.966-967, 2006.

J. F. Kerr, A. H. Wyllie, and A. R. Currie, Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br. J. Cancer, vol.26, pp.239-257, 1972.

H. Khoury, M. A. Naujokas, D. Zuo, V. Sangwan, M. M. Frigault et al., HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion, Mol. Biol. Cell, vol.16, pp.550-561, 2005.

Y. H. Kim, E. M. Jung, T. Lee, S. H. Kim, Y. H. Choi et al., Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic, Biol. Med, vol.44, pp.1055-1068, 2008.

T. Kinugasa, T. Sakaguchi, X. Gu, and H. C. Reinecker, Claudins regulate the intestinal barrier in response to immune mediators, Gastroenterology, vol.118, pp.1001-1011, 2000.

T. Kinugasa, Q. Huo, D. Higashi, H. Shibaguchi, M. Kuroki et al., Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer, Anticancer Res, vol.27, pp.3729-3734, 2007.

K. Kobayashi, Y. Tsugami, K. Matsunaga, S. Oyama, C. Kuki et al., Prolactin and glucocorticoid signaling induces lactation-specific tight junctions concurrent with ?-casein expression in mammary epithelial cells, Biochim. Biophys. Acta, vol.1863, pp.2006-2016, 2016.

T. Kojima, K. Takano, T. Yamamoto, M. Murata, S. Son et al., Transforming growth factor-beta induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes, Liver Int, vol.28, pp.534-545, 2008.

Y. Komatsu, T. Yoshino, K. Yamazaki, S. Yuki, N. Machida et al., Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer, Invest New Drugs, vol.32, pp.473-480, 2014.

J. Kondo, F. Sato, T. Kusumi, Y. Liu, O. Motonari et al., Claudin-1 expression is induced by tumor necrosis factor-alpha in human pancreatic cancer cells, Int. J. Mol. Med, vol.22, pp.645-649, 2008.

M. Koyama, Y. Sowa, M. Horinaka, A. E. Goda, J. Fujiwara et al., Peroxisome proliferatoractivated receptor ? ligand troglitazone and TRAIL synergistically induce apoptosis, Oncol. Rep, vol.31, pp.947-954, 2014.

N. V. Krakhmal, M. V. Zavyalova, E. V. Denisov, S. V. Vtorushin, and V. M. Perelmuter, Cancer Invasion: Patterns and Mechanisms, Acta Naturae, vol.7, pp.17-28, 2015.

F. Krämer, K. White, M. Kubbies, K. Swisshelm, and B. H. Weber, Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer, Hum. Genet, vol.107, pp.249-256, 2000.

G. Krause, L. Winkler, S. L. Mueller, R. F. Haseloff, J. Piontek et al., Structure and function of claudins, Biochim. Biophys. Acta, vol.1778, pp.631-645, 2008.

G. Krause, J. Protze, and J. Piontek, Assembly and function of claudins: Structure-function relationships based on homology models and crystal structures, Semin. Cell Dev. Biol, vol.42, pp.3-12, 2015.

M. Krishnan, A. B. Singh, J. J. Smith, A. Sharma, X. Chen et al., HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability, Oncogene, vol.29, pp.305-312, 2010.

M. Kulawiec, A. Safina, M. M. Desouki, I. Still, S. Matsui et al., Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion, Cancer Biol. Ther, vol.7, pp.1732-1743, 2008.

M. H. Kulke, G. D. Demetri, N. E. Sharpless, D. P. Ryan, R. Shivdasani et al., A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer, Cancer J, vol.8, pp.395-399, 2002.

S. Lamouille, J. Xu, and R. Derynck, Molecular mechanisms of epithelial-mesenchymal transition, Nat. Rev. Mol. Cell Biol, vol.15, pp.178-196, 2014.

N. J. Lane, R. Dallai, G. B. Martinucci, and P. Burighel, Cell junctions in amphioxus (Cephalochordata): a thin section and freeze-fracture study, Tissue Cell, vol.19, pp.399-411, 1987.

J. Langedijk, A. K. Mantel-teeuwisse, D. S. Slijkerman, and M. D. Schutjens, Drug repositioning and repurposing: terminology and definitions in literature, Drug Discov. Today, vol.20, pp.1027-1034, 2015.

T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, vol.367, pp.645-648, 1994.

E. Y. Lasfargues and L. Ozello, Cultivation of human breast carcinomas, J Natl Cancer Inst, vol.21, pp.1131-1147, 1958.

D. A. Lauffenburger and A. F. Horwitz, Cell migration: a physically integrated molecular process, Cell, vol.84, pp.359-369, 1996.

T. Lebret and A. Méjean, Metastases from urologic malignancies: history, definitions and strategies, 2008.

, Prog. Urol, vol.18, issue.7, pp.143-146

J. Lecomte, S. Flament, S. Salamone, M. Boisbrun, S. Mazerbourg et al., Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgammaindependent events in two hormone-dependent breast cancer cell lines, Breast Cancer Res. Treat, vol.112, pp.437-451, 2008.

W. Le-cytosquelette,

C. Leduc, E. , and S. , Intermediate filaments in cell migration and invasion: the unusual suspects, Curr. Opin. Cell Biol, vol.32, pp.102-112, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-02059136

D. B. Lee, N. Jamgotchian, S. G. Allen, M. B. Abeles, and H. J. Ward, A lipid-protein hybrid model for tight junction, Am. J. Physiol. Renal Physiol, vol.295, pp.1601-1612, 2008.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J. Clin. Invest, vol.121, pp.2750-2767, 2011.

J. M. Lehmann, L. B. Moore, T. A. Smith-oliver, W. O. Wilkison, T. M. Willson et al., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma), J. Biol. Chem, vol.270, pp.12953-12956, 1995.

J. Lehtimäki, M. Hakala, and P. Lappalainen, Actin Filament Structures in Migrating Cells, Handb Exp Pharmacol, vol.235, pp.123-152, 2017.

P. D. Leotlela, M. S. Wade, P. H. Duray, M. J. Rhode, H. F. Brown et al., Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility, Oncogene, vol.26, pp.3846-3856, 2007.

G. Letort, H. Ennomani, L. Gressin, M. Théry, and L. Blanchoin, Dynamic reorganization of the actin cytoskeleton, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01600852

J. Li, M. Zhuo, L. Pei, Y. , and A. S. , Conserved aromatic residue confers cation selectivity in claudin-2 and claudin-10b, J. Biol. Chem, vol.288, pp.22790-22797, 2013.

G. Li, P. Flodby, J. Luo, H. Kage, A. Sipos et al., Knockout mice reveal key roles for claudin 18 in alveolar barrier properties and fluid homeostasis, Am J Respir Cell Mol Biol, vol.51, pp.210-232, 2014.

X. Li, W. Liu, X. Chen, Y. Wang, D. Shi et al., Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancer, Int. J. Mol. Med, vol.39, pp.927-935, 2017.

Y. Li, D. Zhang, D. Lin, and L. Cao, Peroxisome proliferator-activated receptor-? inhibits pancreatic cancer cell invasion and metastasis via regulating MMP-2 expression through PTEN, Mol Med Rep, vol.12, pp.6255-6260, 2015.

F. Liu, M. Koval, S. Ranganathan, S. Fanayan, W. S. Hancock et al., Systems Proteomics View of the Endogenous Human Claudin Protein Family, J. Proteome Res, vol.15, pp.339-359, 2016.

H. Liu, C. Zang, M. H. Fenner, K. Possinger, and E. Elstner, PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro, Breast Cancer Res. Treat, vol.79, pp.63-74, 2003.

H. Liu, C. Zang, M. H. Fenner, D. Liu, K. Possinger et al., Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18, Blood, vol.107, pp.3683-3692, 2006.

J. Liu, H. Lu, R. Huang, D. Lin, X. Wu et al., , 2005.

, Peroxisome proliferator activated receptor-? ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells, Cancer Chemother Pharmacol, vol.56, pp.400-408

Y. Liu, L. Wang, X. Lin, J. Wang, J. Yu et al., Anti-apoptotic effect of claudin-1 on TNF-?-induced apoptosis in human breast cancer MCF-7 cells, Tumour Biol, vol.33, pp.2307-2315, 2012.

Y. Liu, Y. Miao, J. Wang, X. Lin, L. Wang et al., DEC1 is positively associated with the malignant phenotype of invasive breast cancers and negatively correlated with the expression of claudin-1, Int. J. Mol. Med, vol.31, pp.855-860, 2013.

T. Lopardo, N. Lo-iacono, B. Marinari, M. L. Giustizieri, D. G. Cyr et al., Claudin-1 is a p63 target gene with a crucial role in epithelial development, PLoS ONE, vol.3, 2008.

M. A. Lopez-ramirez, D. Wu, G. Pryce, J. E. Simpson, A. Reijerkerk et al., MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation, FASEB J, vol.28, pp.2551-2565, 2014.

S. Lu, K. Singh, S. Mangray, R. Tavares, L. Noble et al., Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype, Mod. Pathol, vol.26, pp.485-495, 2013.

R. D. Lynch, S. A. Francis, K. M. Mccarthy, E. Casas, C. Thiele et al., Cholesterol depletion alters detergent-specific solubility profiles of selected tight junction proteins and the phosphorylation of occludin, Exp. Cell Res, vol.313, pp.2597-2610, 2007.

M. ,

L. Ma and R. A. Weinberg, Micromanagers of malignancy: role of microRNAs in regulating metastasis, Trends Genet, vol.24, pp.448-456, 2008.

D. Ma, Y. Jiang, X. Liu, Y. Liu, and . Shao, Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer, Breast Cancer Res. Treat, vol.162, pp.39-48, 2017.

F. Ma, X. Ding, Y. Fan, J. Ying, S. Zheng et al., A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer, PLoS ONE, vol.9, 2014.

J. L. Madara and J. R. Pappenheimer, Structural basis for physiological regulation of paracellular pathways in intestinal epithelia, J. Membr. Biol, vol.100, pp.149-164, 1987.

J. L. Madara, D. Barenberg, and S. Carlson, Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity, J. Cell Biol, vol.102, pp.2125-2136, 1986.

J. L. Madara, J. Stafford, D. Barenberg, and S. Carlson, Functional coupling of tight junctions and microfilaments in T84 monolayers, Am. J. Physiol, vol.254, pp.416-423, 1988.

G. Magenta, X. Borenstein, R. Rolando, and M. A. Jasnis, Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3, BMC Cancer, vol.8, p.47, 2008.

S. Mahati, L. Xiao, Y. Yang, R. Mao, B. et al., miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1, Biochem. Biophys. Res. Commun, vol.486, pp.732-737, 2017.

A. Majer, A. A. Blanchard, S. Medina, S. A. Booth, and Y. Myal, Claudin 1 Expression Levels Affect miRNA Dynamics in Human Basal-Like Breast Cancer Cells, DNA Cell Biol, vol.35, pp.328-339, 2016.

A. J. Mangan, D. V. Sietsema, D. Li, J. K. Moore, S. Citi et al., Cingulin and actin mediate midbody-dependent apical lumen formation during polarization of epithelial cells. Nat Commun 7, 12426. the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells, J. Cell. Physiol, vol.192, pp.268-275, 2016.

T. A. Martin, G. Watkins, R. E. Mansel, and W. G. Jiang, Hepatocyte growth factor disrupts tight junctions in human breast cancer cells, Cell Biol. Int, vol.28, pp.361-371, 2004.

O. M. Martínez-estrada, A. Cullerés, F. X. Soriano, H. Peinado, V. Bolós et al., The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells, Biochem. J, vol.394, pp.449-457, 2006.

Y. Masubuchi, Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review, Drug Metab. Pharmacokinet, vol.21, pp.347-356, 2006.

S. Mazerbourg, S. Kuntz, I. Grillier-vuissoz, A. Berthe, M. Geoffroy et al., Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?, Curr Top Med Chem, vol.16, pp.2115-2124, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01281602

K. M. Mccarthy, S. A. Francis, J. M. Mccormack, J. Lai, R. A. Rogers et al., Inducible expression of claudin-1-myc but not occludin-VSV-G results in aberrant tight junction strand formation in MDCK cells, J. Cell. Sci. 113 Pt, vol.19, pp.3387-3398, 2000.

M. Mego, S. A. Mani, and M. Cristofanilli, Molecular mechanisms of metastasis in breast cancer--clinical applications, Nat Rev Clin Oncol, vol.7, pp.693-701, 2010.

J. Meshki, S. D. Douglas, J. Lai, L. Schwartz, L. E. Kilpatrick et al., Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism, J. Biol. Chem, vol.284, pp.9280-9289, 2009.

I. Meza, G. Ibarra, M. Sabanero, A. Martínez-palomo, and M. Cereijido, Occluding junctions and cytoskeletal components in a cultured transporting epithelium, J. Cell Biol, vol.87, pp.746-754, 1980.

D. W. Miles, A. Chan, L. Y. Dirix, J. Cortés, X. Pivot et al., Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J. Clin. Oncol, vol.28, pp.3239-3247, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00508083

K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh et al., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N. Engl. J. Med, vol.357, pp.2666-2676, 2007.

K. Mineta, Y. Yamamoto, Y. Yamazaki, H. Tanaka, Y. Tada et al., Predicted expansion of the claudin multigene family, FEBS Lett, vol.585, pp.606-612, 2011.

S. L. Mironov, M. V. Ivannikov, J. , and M. , [Ca2+]i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules. From mitochondrial permeability transition pore to Ca2+-induced Ca2+ release, J. Biol. Chem, vol.280, pp.715-721, 2005.

N. Miwa, M. Furuse, S. Tsukita, N. Niikawa, Y. Nakamura et al., Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers, Oncol. Res, vol.12, pp.469-476, 2001.

H. Miyamori, T. Takino, Y. Kobayashi, H. Tokai, Y. Itoh et al., Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases, J. Biol. Chem, vol.276, pp.28204-28211, 2001.

M. Monami, I. Dicembrini, and E. Mannucci, Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials, Acta Diabetol, vol.51, pp.91-101, 2014.

P. J. Morin, Claudin proteins in human cancer: promising new targets for diagnosis and therapy, Cancer Res, vol.65, pp.9603-9606, 2005.

S. Morohashi, T. Kusumi, F. Sato, H. Odagiri, H. Chiba et al., Decreased expression of claudin-1 correlates with recurrence status in breast cancer, Int. J. Mol. Med, vol.20, pp.139-143, 2007.

W. Motomura, M. Nagamine, S. Tanno, M. Sawamukai, N. Takahashi et al., Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells, J. Gastroenterol, vol.39, pp.461-468, 2004.

W. Motomura, N. Takahashi, M. Nagamine, M. Sawamukai, S. Tanno et al., , 2004.

, Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells, Int. J. Cancer, vol.108, pp.41-46

E. Mueller, M. Smith, P. Sarraf, T. Kroll, A. Aiyer et al., Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer, Proc. Natl. Acad. Sci. U.S.A, vol.97, pp.10990-10995, 2000.

D. A. Murphy and S. A. Courtneidge, The "ins" and "outs" of podosomes and invadopodia: characteristics, formation and function, Nat. Rev. Mol. Cell Biol, vol.12, pp.413-426, 2011.

K. Nadarajan, P. Balaram, and B. Y. Khoo, MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPAR?/?, FGF4 and 5LOX, Cytotechnology, vol.68, pp.1771-1787, 2016.

M. Nagano, D. Hoshino, N. Koshikawa, T. Akizawa, and M. Seiki, Turnover of focal adhesions and cancer cell migration, Int J Cell Biol, p.310616, 2012.

S. Nath, D. , and G. R. , Three-dimensional culture systems in cancer research: Focus on tumor spheroid model, Pharmacol. Ther, vol.163, pp.94-108, 2016.

M. A. Nieto, R. Y. Huang, .. Jackson, R. A. Thiery, and J. P. , Cell, vol.166, pp.21-45, 2016.

S. Nik-zainal, H. Davies, J. Staaf, M. Ramakrishna, D. Glodzik et al., Landscape of somatic mutations in 560 breast cancer whole-genome sequences, Nature, vol.534, pp.47-54, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01388447

I. Ninomiya, K. Yamazaki, K. Oyama, H. Hayashi, H. Tajima et al., Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells, Oncol Lett, vol.8, pp.2709-2714, 2014.

M. Nita-lazar, I. Rebustini, J. Walker, and M. A. Kukuruzinska, Hypoglycosylated E-cadherin promotes the assembly of tight junctions through the recruitment of PP2A to adherens junctions, Exp. Cell Res, vol.316, pp.1871-1884, 2010.

P. C. Nowell, The clonal evolution of tumor cell populations, Science, vol.194, pp.23-28, 1976.

V. Nunbhakdi-craig, T. Machleidt, E. Ogris, D. Bellotto, C. L. White et al., Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex, J. Cell Biol, vol.158, pp.967-978, 2002.

N. Ogasawara, T. Kojima, M. Go, T. Ohkuni, J. Koizumi et al., PPARgamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells, Pharmacol. Res, vol.61, pp.489-498, 2010.

N. Oku, E. Sasabe, E. Ueta, T. Yamamoto, and T. Osaki, Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1, Cancer Res, vol.66, pp.5251-5257, 2006.

E. A. O'reilly, L. Gubbins, S. Sharma, R. Tully, M. H. Guang et al., The fate of chemoresistance in triple negative breast cancer (TNBC), 2015.

, BBA Clin, vol.3, pp.257-275

M. Osanai, A. Takasawa, M. Murata, and N. Sawada, Claudins in cancer: bench to bedside, Pflugers Arch, vol.469, pp.55-67, 2017.

S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation, Cancer Res, vol.61, pp.6213-6218, 2001.

H. Peinado, D. Olmeda, and A. Cano, Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?, Nat. Rev. Cancer, vol.7, pp.415-428, 2007.

C. M. Perou, Molecular stratification of triple-negative breast cancers, Oncologist, vol.15, pp.39-48, 2010.

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular portraits of human breast tumours, Nature, vol.406, pp.747-752, 2000.

P. Pinto-da-silva and B. Kachar, On tight-junction structure, Cell, vol.28, pp.441-450, 1982.

J. Piontek, L. Winkler, H. Wolburg, S. L. Müller, N. Zuleger et al., Formation of tight junction: determinants of homophilic interaction between classic claudins, FASEB J, vol.22, pp.146-158, 2008.

M. J. Pishvaian, J. L. Marshall, A. J. Wagner, J. J. Hwang, S. Malik et al., A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies, Cancer, vol.118, pp.5403-5413, 2012.

M. L. Plissonnier, S. Fauconnet, H. Bittard, and I. Lascombe, Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells, Int. J. Cancer, vol.127, pp.1769-1784, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00485114

M. Plissonnier, S. Fauconnet, H. Bittard, and I. Lascombe, The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL, PLoS ONE, vol.6, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00719596

L. S. Poritz, L. R. Harris, A. A. Kelly, and W. A. Koltun, Increase in the tight junction protein claudin-1 in intestinal inflammation, Dig. Dis. Sci, vol.56, pp.2802-2809, 2011.

A. Prat, J. S. Parker, O. Karginova, C. Fan, C. Livasy et al., , 2010.

, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res, vol.12, p.68

M. G. Price, C. F. Davis, F. Deng, and D. L. Burgess, The alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate receptor trafficking regulator "stargazin" is related to the claudin family of proteins by Its ability to mediate cell-cell adhesion, J. Biol. Chem, vol.280, pp.19711-19720, 2005.

S. Prost, F. Relouzat, M. Spentchian, Y. Ouzegdouh, J. Saliba et al., Erosion of the chronic myeloid leukaemia stem cell pool by PPAR? agonists, Nature, vol.525, pp.380-383, 2015.

W. Qin, Q. Ren, T. Liu, Y. Huang, W. et al., MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1, FEBS Lett, vol.587, pp.1434-1439, 2013.

D. R. Raleigh, A. M. Marchiando, Y. Zhang, L. Shen, H. Sasaki et al., Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions, Mol. Biol. Cell, vol.21, pp.1200-1213, 2010.

J. Rassat, H. Robenek, and H. Themann, Alterations of tight and gap junctions in mouse hepatocytes following administration of colchicine, Cell Tissue Res, vol.223, pp.187-200, 1982.

J. Rassat, H. Robenek, and H. Themann, Cytochalasin B affects the gap and tight junctions of mouse hepatocytes in vivo, J. Submicrosc. Cytol, vol.14, pp.427-439, 1982.

N. J. Robert, V. Diéras, J. Glaspy, A. M. Brufsky, I. Bondarenko et al., RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer, J. Clin. Oncol, vol.29, pp.1252-1260, 2011.

M. Robson, S. Im, E. Senkus, B. Xu, S. M. Domchek et al., Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, N. Engl. J. Med, vol.377, pp.523-533, 2017.

L. S. Rodgers, M. T. Beam, J. M. Anderson, and A. S. Fanning, Epithelial barrier assembly requires coordinated activity of multiple domains of the tight junction protein ZO-1, J. Cell. Sci, vol.126, pp.1565-1575, 2013.

A. Roy, S. A. Ansari, K. Das, R. Prasad, A. Bhattacharya et al., , 2017.

, Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to ?-catenin accumulation via the AKT/GSK3? pathway and contributes to breast cancer progression, J. Biol. Chem, vol.292, pp.13688-13701

W. A. Russu, Thiazolidinedione anti-cancer activity: Is inhibition of microtubule assembly implicated?, Med. Hypotheses, vol.68, pp.343-346, 2007.

B. J. Saeedi, D. J. Kao, D. A. Kitzenberg, E. Dobrinskikh, K. D. Schwisow et al., HIF-dependent regulation of claudin-1 is central to intestinal epithelial tight junction integrity, Mol. Biol. Cell, vol.26, pp.2252-2262, 2015.

S. Saha, L. S. New, H. K. Ho, W. K. Chui, C. et al., Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity, Toxicol. Lett, vol.192, pp.141-149, 2010.

S. Salamone, C. Colin, I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg et al., Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study, Eur J Med Chem, vol.51, pp.206-215, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00746870

A. Seth, P. Sheth, B. C. Elias, and R. Rao, Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer, J. Biol. Chem, vol.282, pp.11487-11498, 2007.

M. Shackleton, F. Vaillant, K. J. Simpson, J. Stingl, G. K. Smyth et al., Generation of a functional mammary gland from a single stem cell, Nature, vol.439, pp.84-88, 2006.

A. Sharma, A. A. Bhat, M. Krishnan, A. B. Singh, and P. Dhawan, Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells, Carcinogenesis, vol.34, pp.2610-2621, 2013.

C. Shiau, C. Yang, S. K. Kulp, K. Chen, C. Chen et al., , 2005.

, Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma, Cancer Res, vol.65, pp.1561-1569

S. Shiou, A. B. Singh, K. Moorthy, P. K. Datta, M. K. Washington et al.,

, Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells, Cancer Res, vol.67, pp.1571-1579

L. I. Shlush and D. Hershkovitz, Clonal evolution models of tumor heterogeneity, Am Soc Clin Oncol Educ Book, pp.662-665, 2015.

A. B. Singh and R. C. Harris, Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells, J. Biol. Chem, vol.279, pp.3543-3552, 2004.

S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins et al., Identification of a cancer stem cell in human brain tumors, Cancer Res, vol.63, pp.5821-5828, 2003.

S. K. Singh, C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani et al., Identification of human brain tumour initiating cells, Nature, vol.432, pp.396-401, 2004.

S. Sluysmans, E. Vasileva, D. Spadaro, J. Shah, F. Rouaud et al., The role of apical cell-cell junctions and associated cytoskeleton in mechanotransduction, Biol. Cell, vol.109, pp.139-161, 2017.

G. H. Smith, Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands, Development, vol.132, pp.681-687, 2005.

G. Sobel, J. Németh, A. Kiss, G. Lotz, I. Szabó et al., Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma, Gynecol. Oncol, vol.103, pp.591-598, 2006.

T. Sohda, K. Mizuno, E. Imamiya, Y. Sugiyama, T. Fujita et al., Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives, Chem. Pharm. Bull, vol.30, pp.3580-3600, 1982.

H. D. Soule, J. Vazquez, A. Long, S. Albert, and M. Brennan, A human cell line from a pleural effusion derived from a breast carcinoma, J Natl Cancer Inst, vol.51, pp.1409-1416, 1973.

H. D. Soule, T. M. Maloney, S. R. Wolman, W. D. Peterson, R. Brenz et al., Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10, Cancer Res, vol.50, pp.6075-6086, 1990.

T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci. U.S.A, vol.98, pp.10869-10874, 2001.

T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc. Natl. Acad. Sci. U.S.A, vol.100, pp.8418-8423, 2003.

D. Spadaro, R. Tapia, L. Jond, M. Sudol, A. S. Fanning et al., ZO proteins redundantly regulate the transcription factor DbpA/ZONAB, J. Biol. Chem, vol.289, pp.22500-22511, 2014.

L. A. Staehelin, Further observations on the fine structure of freeze-cleaved tight junctions, J. Cell. Sci, vol.13, pp.763-786, 1973.

B. R. Stevenson, J. D. Siliciano, M. S. Mooseker, and D. A. Goodenough, Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia, J. Cell Biol, vol.103, pp.755-766, 1986.

J. Stingl, P. Eirew, I. Ricketson, M. Shackleton, F. Vaillant et al., Purification and unique properties of mammary epithelial stem cells, Nature, vol.439, pp.993-997, 2006.

H. Suzuki, T. Nishizawa, K. Tani, Y. Yamazaki, A. Tamura et al., Crystal structure of a claudin provides insight into the architecture of tight junctions, Science, vol.344, pp.304-307, 2014.

K. Swisshelm, A. Machl, S. Planitzer, R. Robertson, M. Kubbies et al., SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily, Gene, vol.226, pp.285-295, 1999.

A. M. Szasz, A. M. Tokes, M. Micsinai, T. Krenacs, C. Jakab et al., Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis, Clin. Exp. Metastasis, vol.28, pp.55-63, 2011.

, for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?, Int J Mol Sci, vol.18

M. Tuccori, K. B. Filion, H. Yin, O. H. Yu, R. W. Platt et al., Pioglitazone use and risk of bladder cancer: population based cohort study, BMJ, vol.352, 1541.

C. M. Van-itallie, A. , and J. M. , Architecture of tight junctions and principles of molecular composition, Semin. Cell Dev. Biol, vol.36, pp.157-165, 2014.

C. M. Van-itallie, A. J. Tietgens, A. , and J. M. , Visualizing the dynamic coupling of claudin strands to the actin cytoskeleton through ZO-1, Mol. Biol. Cell, vol.28, pp.524-534, 2017.

C. M. Van-itallie, A. S. Fanning, A. Bridges, A. , and J. M. , ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton, Mol. Biol. Cell, vol.20, pp.3930-3940, 2009.

C. L. Varley, M. A. Garthwaite, W. Cross, J. Hinley, L. K. Trejdosiewicz et al., , 2006.

, PPARgamma-regulated tight junction development during human urothelial cytodifferentiation, J. Cell. Physiol, vol.208, pp.407-417

J. E. Visvader and J. Stingl, Mammary stem cells and the differentiation hierarchy: current status and perspectives, Genes Dev, vol.28, pp.1143-1158, 2014.

F. Wang, D. Liu, H. Xu, Y. Li, W. Wang et al., Thapsigargin induces apoptosis by impairing cytoskeleton dynamics in human lung adenocarcinoma cells, ScientificWorldJournal, p.619050, 2014.

H. Wang, P. Wang, X. Wang, Y. Wan, and Y. Liu, Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription, Dig. Dis. Sci, vol.57, pp.3126-3135, 2012.

P. Wang, F. Chou, L. Porchia, M. Saji, and J. J. Pinzone, Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells, Mol. Carcinog, vol.47, pp.905-915, 2008.

Y. Wang, M. P. Mattson, and K. Furukawa, Endoplasmic reticulum calcium release is modulated by actin polymerization, J. Neurochem, vol.82, pp.945-952, 2002.

C. J. Watson, C. J. Hoare, D. R. Garrod, G. L. Carlson, and G. Warhurst, Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores, J. Cell. Sci, vol.118, pp.5221-5230, 2005.

S. Wei, L. Lin, C. Yang, Y. Wang, G. Chang et al., , 2007.

, Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferatoractivated receptor gamma, Mol. Pharmacol, vol.72, pp.725-733

X. Wei, Z. Jia, J. Lian, Y. Zhang, J. Li et al., Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1, J. Interferon Cytokine Res, vol.29, pp.171-178, 2009.

B. Weigelt, C. K. Ng, R. Shen, T. Popova, M. Schizas et al., Corrigendum: metastatic breast carcinomas display genomic and transcriptomic heterogeneity, Mod. Pathol, vol.28, p.607, 2015.

H. Wen, D. D. Watry, M. C. Marcondes, and H. S. Fox, Selective decrease in paracellular conductance of tight junctions: role of the first extracellular domain of claudin-5, Mol. Cell. Biol, vol.24, pp.8408-8417, 2004.

X. Wu, H. Chen, B. Parker, E. Rubin, T. Zhu et al., HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition, Cancer Res, vol.66, pp.9527-9534, 2006.

K. M. Yamada, A. , and M. , Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis, J. Cell. Sci, vol.114, pp.2375-2382, 2001.

Y. Yang, L. Zhao, B. Huang, R. Wang, S. Yuan et al., Pioglitazone, a PPAR? agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling, Mol. Carcinog, vol.54, pp.1584-1595, 2015.

Y. Yang, T. Ho, S. Chen, H. Lai, J. Wu et al., Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line, BMC Cancer, vol.7, p.216, 2007.

T. Yano, T. Matsui, A. Tamura, M. Uji, and S. Tsukita, The association of microtubules with tight junctions is promoted by cingulin phosphorylation by AMPK, J. Cell Biol, vol.203, pp.605-614, 2013.

A. Yates, W. Akanni, M. R. Amode, D. Barrell, K. Billis et al., Nucleic Acids Res, vol.44, pp.710-716, 2016.

L. D. Yee, N. Williams, P. Wen, D. C. Young, J. Lester et al., Pilot study of rosiglitazone therapy in women with breast cancer: effects of shortterm therapy on tumor tissue and serum markers, Clin. Cancer Res, vol.13, pp.246-252, 2007.

S. Yoda, K. Soejima, J. Hamamoto, H. Yasuda, S. Nakayama et al., Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer, Lung Cancer, vol.85, pp.366-372, 2014.

K. Zhang, H. Yao, and M. Wang, Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility, Carcinogenesis, vol.29, pp.552-559, 2008.

W. Zhang, N. Wu, Z. Li, L. Wang, J. Jin et al., PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404, Cancer Biol. Ther, vol.5, pp.1008-1014, 2006.

X. Zhao, Y. Zou, Q. Gu, G. Zhao, H. Gray et al., Lentiviral Vector Mediated Claudin1 Silencing Inhibits Epithelial to Mesenchymal Transition in Breast Cancer Cells, Viruses, vol.7, pp.2965-2979, 2015.

G. Zheng, G. Victor-fon, W. Meixner, A. Creekmore, Y. Zong et al., Chronic stress and intestinal barrier dysfunction: Glucocorticoid receptor and transcription repressor HES1 regulate tight junction protein Claudin-1 promoter, vol.7, p.4502, 2017.

B. Zhou, A. Blanchard, N. Wang, X. Ma, J. Han et al., Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7, Cancer Invest, vol.33, pp.429-439, 2015.

B. Zhou, A. Moodie, A. A. Blanchard, E. Leygue, and Y. Myal, Claudin 1 in Breast Cancer: New Insights, J Clin Med, vol.4, pp.1960-1976, 2015.

Q. Zhou, S. Costinean, C. M. Croce, A. R. Brasier, S. Merwat et al., MicroRNA 29 targets nuclear factor-?B-repressing factor and Claudin 1 to increase intestinal permeability, Gastroenterology, vol.148, pp.158-169, 2015.

J. Zhu, Y. Zhang, W. Zhang, W. Zhang, L. Fan et al., , 2016.

, MicroRNA-142-5p contributes to Hashimoto's thyroiditis by targeting CLDN1, J Transl Med, vol.14, p.166

Y. Zhu, W. Wang, T. Yuan, L. Fu, L. Zhou et al., , 2017.

, MicroRNA-29a mediates the impairment of intestinal epithelial integrity induced by intrauterine growth restriction in pig, Am. J. Physiol. Gastrointest. Liver Physiol, vol.312, pp.434-442

C. Zihni, C. Mills, K. Matter, and M. S. Balda, Tight junctions: from simple barriers to multifunctional molecular gates, Nat. Rev. Mol. Cell Biol, vol.17, pp.564-580, 2016.

W. Zou, X. Liu, P. Yue, F. R. Khuri, and S. Sun, PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells, Cancer Biol. Ther, vol.6, pp.99-106, 2007.

D. Zwanziger, J. Badziong, S. Ting, L. C. Moeller, K. W. Schmid et al., The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness, Endocr. Relat. Cancer, vol.22, pp.819-830, 2015.

L. Des and . Scientifiques,

S. Mazerbourg, S. Kuntz, I. Grillier-vuissoz, A. Berthe, M. Geoffroy et al., Reprofiling of Troglitazone towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?, Current Topics in Medicinal Chemistry, vol.16, issue.19, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01281602

M. Geoffroy, A. Kleinclauss, S. Grandemange, S. Hupont, M. Boisbrun et al., Pro-apoptotic effect of ?2-TGZ in "claudin 1-low" triple negative breast cancer cells: involvement of claudin 1, Breast Cancer Research and Treatment, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01589665

, , vol.165, pp.517-527

M. *. Geoffroy, G. Husson, A. Kleinclauss, M. Boisbrun, S. Flament et al.,

S. Kuntz, Les dérivés de TZD: une piste prometteuse pour le traitement des tumeurs triplenégatives "claudine 1 low" ? Journée d'Echanges sur la Recherche en Cancérologie en

L. , La personnalisation du diagnostic et des traitements, Institut de Cancérologie de Lorraine à Vandoeuvre les Nancy, 26 septembre, 2014.

M. *. Geoffroy, G. Husson, A. Kleinclauss, M. Boisbrun, S. Flament et al.,

M. *. Geoffroy, G. Husson, A. Kleinclauss, M. Boisbrun, S. Flament et al.,

S. Kuntz, Les dérivés de TZD: une piste prometteuse pour le traitement des tumeurs triplenégatives "claudine 1 low" ? Journée d'échanges sur la recherche en cancérologie en Lorraine

, La personnalisation du diagnostic et des traitements. Institut de Cancérologie de Lorraine à Vandoeuvre les Nancy, 26 septembre, 2015.

I. Grillier-vuissoz, S. Kuntz, S. Mazerbourg, C. Colin-cassin, M. Geoffroy et al., une stratégie intéressante pour le traitement des tumeurs mammaires triple-négatives? 3 ème Journée d'échanges sur la recherche en cancérologie en Lorraine à Vandoeuvre les Nancy, pp.14-2016

M. *. Geoffroy, A. Kleinclauss, L. Batista, M. Boisbrun, M. Barberi-heyob et al.,

S. Flament, I. Grillier-vuissoz, and S. Kuntz, Effets précoces et tardifs des dérivés de troglitazone

M. Geoffroy, G. Husson, A. Kleinclauss, M. Boisbrun, S. Flament et al.,

S. Kuntz, Thiazolidinediones derivatives: a promising compounds for the treatment of claudin
URL : https://hal.archives-ouvertes.fr/hal-01242191

M. Geoffroy, G. Husson, A. Kleinclauss, M. Boisbrun, S. Flament et al.,

S. Kuntz, Modulation of claudin-1 expression by thiazolidinediones in breast cancer cells. 2 nd International Cancer Research Center of Lyon Symposium, pp.21-23, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01242179

M. Geoffroy, A. Kleinclauss, M. Boisbrun, S. Flament, S. Kuntz et al.,

E. Conference, Making it Personal: Cancer Precision Medicine, pp.13-16, 2017.

M. Prix-de-la-meilleure-;-geoffroy, A. Kleinclauss, and S. Kuntz,

I. Grillier-vuissoz, Rôle de la claudine 1 dans les effets anti-cancéreux des thiazolidinediones dans les cellules cancéreuses mammaires, 2015.